How Lilly’s sustainability goals come face to face with massive growth

To meet raging demand for GLP-1 drugs, Lilly has expanded its manufacturing footprint substantially, committing more than $18 billion to facilities across the U.S. and Europe — building, upgrading and acquiring with an eye toward sustainability. From solar power to AI-driven efficiencies, the company is working toward a 2030 goal of carbon neutrality through renewable energy.